-
Amgen Inc. et al v. Sandoz Inc. et al DC CAFC
- 3:16-cv-02581
- N.D. Cal.
- Judge: Richard Seeborg
- Filed: 05/12/2016
- Closed: 01/08/2018
- Latest Docket Entry: 09/11/2019
- PACER
- Docket updated daily
2
Plaintiffs
4
Defendants
2
Accused
Products
2
Patents-in-Suit
607
Days in
Litigation
-
Amgen Inc. et al v. Sandoz Inc. et al DC CAFC
- 3:16-cv-02581
- N.D. Cal.
- Judge: Richard Seeborg
- Filed: 05/12/2016
- Closed: 01/08/2018
- Latest Docket Entry: 09/11/2019
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Assigned Judge
Outcome Summary
- Patent Information
-
Infringement
Lek Pharmaceuticals, d.d.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Filgrastim biosimilar productPegfilgrastim ProductZarxio | US 8,940,878 B2 | All Asserted Claims |
No infringement
Entry 187Entry 183 |
Sandoz GmbH
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Filgrastim biosimilar productPegfilgrastim ProductZarxio | US 8,940,878 B2 | All Asserted Claims |
No infringement
Entry 187Entry 183 |
Sandoz Inc.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Filgrastim biosimilar productPegfilgrastim ProductZarxio | US 8,940,878 B2 | All Asserted Claims |
No infringement
Entry 187Entry 183 |
Sandoz International GmbH
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Filgrastim biosimilar productPegfilgrastim ProductZarxio | US 8,940,878 B2 | All Asserted Claims |
No infringement
Entry 187Entry 183 |
